NPSP is one of my bio basket investments but I'm looking to add to it and make it a full investment position. On Friday the stock didn't move much given FBR Capital initiating coverage with an overweight rating. Company is transitioning to a profitable entity with minimal dilution risk. Gattex is currently showing solid sales and a 2nd drug, Natpara is in stage 3 clinical trials with possible FDA approval by end of this year. Additional information will be posted here.
Disclosure: The author is long NPSP.